Advisory Committee on the Medical Uses of Isotopes: Meeting Notice, 9484 [2020-03177]

Download as PDF 9484 Federal Register / Vol. 85, No. 33 / Wednesday, February 19, 2020 / Notices on propeller tips, a flotation device if operated over water, and an ‘‘auto go home’’ feature in case of loss of control link or low battery; having an observer on the lookout for wildlife, people, and other hazards; and ensuring that the separation between the operator and quadcopter does not exceed an operational range of 500 meters. The applicant is seeking a Waste Permit to cover any accidental releases that may result from operating the RPAS and ATVs. All waste materials produced during the marathon activity would be collected and mitigation measures would be in place to reduce the possibility of waste release. The applicant would provide temporary, portable toilet facilities to marathon participants. All human waste generated would be returned to the ship for disposal. Location: King George Island, Antarctica. Dates of Permitted Activities: March 23–April 10, 2020. Erika N. Davis, Program Specialist, Office of Polar Programs. [FR Doc. 2020–03165 Filed 2–18–20; 8:45 am] BILLING CODE 7555–01–P NUCLEAR REGULATORY COMMISSION Advisory Committee on the Medical Uses of Isotopes: Meeting Notice U.S. Nuclear Regulatory Commission. ACTION: Notice of meeting. khammond on DSKJM1Z7X2PROD with NOTICES AGENCY: The U.S. Nuclear Regulatory Commission (NRC) will convene a meeting of the Advisory Committee on the Medical Uses of Isotopes (ACMUI) on March 30–31, 2020. A sample of agenda items to be discussed during the public session includes: (1) A discussion on medical-related events; (2) a discussion on the ACMUI’s recommendations regarding the definition of patient intervention and other actions exclusive of medical events; (3) a discussion on the U.S. Federal Drug Administration’s regulatory process for drugs and devices; (4) a discussion on the overview of the NRC’s Nuclear Material Events Database; (5) a discussion on the status of emerging and trending radiopharmaceuticals; and (6) a discussion on the ACMUI’s recommendations on the need for an interventional radiologist representative position on the ACMUI. The agenda is subject to change. The current agenda and any updates will be VerDate Sep<11>2014 18:58 Feb 18, 2020 Jkt 250001 available at https://www.nrc.gov/ reading-rm/doc-collections/acmui/ meetings/2020.html or by emailing Ms. Kellee Jamerson at the contact information below. Purpose: Discuss issues related to 10 CFR part 35 Medical Use of Byproduct Material. Date and Time: March 30, 2020 from 8:30 a.m. to 2:45 p.m. and March 31, 2020 from 8:30 a.m. to 2:00 p.m. Eastern Standard Time. Address for Public Meeting: U.S. Nuclear Regulatory Commission, Two White Flint North Building, Room T– 2D30, 11545 Rockville Pike, Rockville, Maryland 20852. Public Participation: Any member of the public who wishes to participate in the meeting in person or via phone should contact Ms. Jamerson using the information below. The meeting will also be webcast live from the NRC’s Webcast Portal at https://video.nrc. gov/. Contact Information: Ms. Kellee Jamerson, email: Kellee.Jamerson@ nrc.gov, telephone: (301) 415–7408. Conduct of the Meeting Darlene F. Metter, M.D. will chair the meeting. Dr. Metter will conduct the meeting in a manner that will facilitate the orderly conduct of business. The following procedures apply to public participation in the meeting: 1. Persons who wish to provide a written statement should submit an electronic copy to Ms. Jamerson using the contact information listed above. All submittals must be received by March 25, 2020, three business days before the meeting, and must pertain to the topics on the agenda for the meeting. 2. Questions and comments from members of the public will be permitted during the meeting, at the discretion of the ACMUI Chairman. 3. The draft transcript and meeting summary will be available on the ACMUI’s website https://www.nrc.gov/ reading-rm/doc-collections/acmui/ meetings/2020.html on or about May 12, 2020. 4. Persons who require special services, such as those for the hearing impaired, should notify Ms. Jamerson of their planned attendance. This meeting will be held in accordance with the Atomic Energy Act of 1954, as amended (primarily Section 161a); the Federal Advisory Committee Act (5 U.S.C. App); and the Commission’s regulations in title 10 of the Code of Federal Regulations, Part 7. Dated at Rockville, Maryland this 12th day of February, 2020. PO 00000 Frm 00034 Fmt 4703 Sfmt 4703 For the U.S. Nuclear Regulatory Commission. Russell E. Chazell, Advisory Committee Management Officer. [FR Doc. 2020–03177 Filed 2–18–20; 8:45 am] BILLING CODE 7590–01–P NUCLEAR REGULATORY COMMISSION [NRC–2012–0110] An Approach for Plant-Specific, RiskInformed Decisionmaking: Technical Specifications Nuclear Regulatory Commission. ACTION: Draft regulatory guide; request for comment. AGENCY: The U.S. Nuclear Regulatory Commission (NRC) is re-issuing for public comment draft regulatory guide (DG), DG–1287, ‘‘An Approach for Plant-Specific, Risk-Informed Decisionmaking: Technical Specifications.’’ This proposed Revision 2 of Regulatory Guide (RG) 1.177 includes guidance to develop riskinformed applications for technical specification (TS) changes that considers engineering issues and applies risk insights. This proposed revision also provides guidance acceptable to the staff for using risk information to evaluate changes to nuclear power plant TS completion times (CTs) and surveillance frequencies (SFs) and to assess the impact of such proposed changes on the risk associated with plant operation. This DG–1287 supplements the guidance provided in RG 1.174, ‘‘An Approach for Using Probabilistic Risk Assessment in RiskInformed Decisions on Plant-Specific Changes to the Licensing Basis,’’ Revision 3, issued January 2018. DATES: Submit comments by April 20, 2020. Comments received after this date will be considered if it is practical to do so, but the NRC is able to ensure consideration only for comments received on or before this date. Although a time limit is given for public comment, comments and suggestions in connection with items for inclusion in RGs currently being developed or improvements in all published RGs are encouraged at any time. SUMMARY: You may submit comments by any of the following methods: • Federal Rulemaking Website: Go to https://www.regulations.gov and search for Docket ID NRC–2012–0110. Address questions about NRC docket IDs in Regulations.gov to Jennifer Borges; ADDRESSES: E:\FR\FM\19FEN1.SGM 19FEN1

Agencies

[Federal Register Volume 85, Number 33 (Wednesday, February 19, 2020)]
[Notices]
[Page 9484]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-03177]


=======================================================================
-----------------------------------------------------------------------

NUCLEAR REGULATORY COMMISSION


Advisory Committee on the Medical Uses of Isotopes: Meeting 
Notice

AGENCY: U.S. Nuclear Regulatory Commission.

ACTION: Notice of meeting.

-----------------------------------------------------------------------

    The U.S. Nuclear Regulatory Commission (NRC) will convene a meeting 
of the Advisory Committee on the Medical Uses of Isotopes (ACMUI) on 
March 30-31, 2020. A sample of agenda items to be discussed during the 
public session includes:
    (1) A discussion on medical-related events; (2) a discussion on the 
ACMUI's recommendations regarding the definition of patient 
intervention and other actions exclusive of medical events; (3) a 
discussion on the U.S. Federal Drug Administration's regulatory process 
for drugs and devices; (4) a discussion on the overview of the NRC's 
Nuclear Material Events Database; (5) a discussion on the status of 
emerging and trending radiopharmaceuticals; and (6) a discussion on the 
ACMUI's recommendations on the need for an interventional radiologist 
representative position on the ACMUI.
    The agenda is subject to change. The current agenda and any updates 
will be available at https://www.nrc.gov/reading-rm/doc-collections/acmui/meetings/2020.html or by emailing Ms. Kellee Jamerson at the 
contact information below.
    Purpose: Discuss issues related to 10 CFR part 35 Medical Use of 
Byproduct Material.
    Date and Time: March 30, 2020 from 8:30 a.m. to 2:45 p.m. and March 
31, 2020 from 8:30 a.m. to 2:00 p.m. Eastern Standard Time.
    Address for Public Meeting: U.S. Nuclear Regulatory Commission, Two 
White Flint North Building, Room T-2D30, 11545 Rockville Pike, 
Rockville, Maryland 20852.
    Public Participation: Any member of the public who wishes to 
participate in the meeting in person or via phone should contact Ms. 
Jamerson using the information below. The meeting will also be webcast 
live from the NRC's Webcast Portal at https://video.nrc.gov/ gov/. Contact 
Information: Ms. Kellee Jamerson, email: [email protected], 
telephone: (301) 415-7408.

Conduct of the Meeting

    Darlene F. Metter, M.D. will chair the meeting. Dr. Metter will 
conduct the meeting in a manner that will facilitate the orderly 
conduct of business. The following procedures apply to public 
participation in the meeting:
    1. Persons who wish to provide a written statement should submit an 
electronic copy to Ms. Jamerson using the contact information listed 
above. All submittals must be received by March 25, 2020, three 
business days before the meeting, and must pertain to the topics on the 
agenda for the meeting.
    2. Questions and comments from members of the public will be 
permitted during the meeting, at the discretion of the ACMUI Chairman.
    3. The draft transcript and meeting summary will be available on 
the ACMUI's website https://www.nrc.gov/reading-rm/doc-collections/acmui/meetings/2020.html on or about May 12, 2020.
    4. Persons who require special services, such as those for the 
hearing impaired, should notify Ms. Jamerson of their planned 
attendance.
    This meeting will be held in accordance with the Atomic Energy Act 
of 1954, as amended (primarily Section 161a); the Federal Advisory 
Committee Act (5 U.S.C. App); and the Commission's regulations in title 
10 of the Code of Federal Regulations, Part 7.

    Dated at Rockville, Maryland this 12th day of February, 2020.

    For the U.S. Nuclear Regulatory Commission.
Russell E. Chazell,
Advisory Committee Management Officer.
[FR Doc. 2020-03177 Filed 2-18-20; 8:45 am]
 BILLING CODE 7590-01-P